Abstract
Peptide targeted 64Cu-labelled diagnostic agents for positron emission tomography are viable candidates for molecular imaging of cancer. In a clinical setting, optimal image quality relies on selective tumor uptake of the 64Culabelled radiotracer. The three components of the radiotracer construct – the chelate group, linker and targeting peptide – all influence the biodistribution of the 64Cu-labelled radiotracer in vivo. Low or moderate Cu complex stability in vivo results in transmetallation of 64Cu to endogenous proteins, giving rise to high background activity. The length and the nature of the linker group affect the affinity of the 64Cu-labelled radiotracer for the target receptor. Variations in the peptide sequence can impact on the metabolic stability and therefore the bioavailability and tumor retention of the 64Cu-labelled radiotracer in vivo. Lastly, the hydrophilicity of the construct can influence radiotracer metabolism and clearance pathways. Recent advances in the field of peptide targeted 64Cu-labelled radiopharmaceuticals involve GRPR-targeted and αvβ3 integrin receptor-targeted constructs. These constructs are based on the bombesin peptide sequence and the RGD recognition motif respectively. These examples are reviewed as case studies in the optimisation of 64Cu radiotracer design.
Keywords: Copper-64, radiopharmaceuticals, positron emission tomography, imaging, bombesin, gastrin-releasing peptide receptor, RGD, integrin receptor, Molecular imaging, PET technology, 64Cu2+ complex, somatostatin receptors, integrin v3, 64Cu-chelate complex
Current Topics in Medicinal Chemistry
Title: Peptide Targeted Copper-64 Radiopharmaceuticals
Volume: 11 Issue: 5
Author(s): Michelle T. Ma and Paul S. Donnelly
Affiliation:
Keywords: Copper-64, radiopharmaceuticals, positron emission tomography, imaging, bombesin, gastrin-releasing peptide receptor, RGD, integrin receptor, Molecular imaging, PET technology, 64Cu2+ complex, somatostatin receptors, integrin v3, 64Cu-chelate complex
Abstract: Peptide targeted 64Cu-labelled diagnostic agents for positron emission tomography are viable candidates for molecular imaging of cancer. In a clinical setting, optimal image quality relies on selective tumor uptake of the 64Culabelled radiotracer. The three components of the radiotracer construct – the chelate group, linker and targeting peptide – all influence the biodistribution of the 64Cu-labelled radiotracer in vivo. Low or moderate Cu complex stability in vivo results in transmetallation of 64Cu to endogenous proteins, giving rise to high background activity. The length and the nature of the linker group affect the affinity of the 64Cu-labelled radiotracer for the target receptor. Variations in the peptide sequence can impact on the metabolic stability and therefore the bioavailability and tumor retention of the 64Cu-labelled radiotracer in vivo. Lastly, the hydrophilicity of the construct can influence radiotracer metabolism and clearance pathways. Recent advances in the field of peptide targeted 64Cu-labelled radiopharmaceuticals involve GRPR-targeted and αvβ3 integrin receptor-targeted constructs. These constructs are based on the bombesin peptide sequence and the RGD recognition motif respectively. These examples are reviewed as case studies in the optimisation of 64Cu radiotracer design.
Export Options
About this article
Cite this article as:
T. Ma Michelle and S. Donnelly Paul, Peptide Targeted Copper-64 Radiopharmaceuticals, Current Topics in Medicinal Chemistry 2011; 11 (5) . https://dx.doi.org/10.2174/156802611794785172
DOI https://dx.doi.org/10.2174/156802611794785172 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
AlphaFold in Medicinal Chemistry: Opportunities and Challenges
AlphaFold, a groundbreaking AI tool for protein structure prediction, is revolutionizing drug discovery. Its near-atomic accuracy unlocks new avenues for designing targeted drugs and performing efficient virtual screening. However, AlphaFold's static predictions lack the dynamic nature of proteins, crucial for understanding drug action. This is especially true for multi-domain proteins, ...read more
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Chronic Kidney Disease
The scope of the special thematic issue includes but not limited to the mechanism of chronic kidney disease (CKD), the treatment of renal fibrosis and early diagnosis of CKD and so on. We also welcome manuscripts from other scientific research area with respect to internal medicine. Cell death has been ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Malignancies with Disulfiram (Antabuse): Multidrug Resistance, Angiogenesis, and Proteasome
Current Cancer Drug Targets Flavonoids in Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry The Cross-talk between Tristetraprolin and Cytokines in Cancer
Anti-Cancer Agents in Medicinal Chemistry Protein Targeting Constructs in Alpha Therapy
Current Radiopharmaceuticals Computer Modeling of Brain Tumor Growth
Mini-Reviews in Medicinal Chemistry Cancer and Aids: New Trends in Drug Design and Chemotherapy
Current Computer-Aided Drug Design Colostral Proline-Rich Polypeptides - Immunoregulatory Properties and Prospects of Therapeutic Use in Alzheimers Disease
Current Alzheimer Research Disulfiram's Anticancer Activity: Evidence and Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Protein Extracts from Somaclonal Mistletoe (Viscum Album L.) Callus with Increased Tumor Cytotoxic Activity in Vitro
Current Bioactive Compounds Graphical Abstracts
Letters in Drug Design & Discovery The Development of Copper Radiopharmaceuticals for Imaging and Therapy
Medicinal Chemistry A Critical Transcription Factor NF-κB as a Cancer Therapeutic Target and its Inhibitors as Cancer Treatment Options
Current Medicinal Chemistry LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway
Current Cancer Drug Targets Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Current Pharmaceutical Design The Emerging Role of Vascular Endothelial Growth Factor (VEGF) in Vascular Homeostasis: Lessons from Recent Trials with Anti-VEGF Drugs
Current Vascular Pharmacology Natural Products with Antiangiogenic and Antivasculogenic Mimicry Activity
Mini-Reviews in Medicinal Chemistry Meet Our Editorial Board Member
Current Medicinal Chemistry Embryonic Stem Cell MicroRNAs: Defining Factors in Induced Pluripotent (iPS) and Cancer (CSC) Stem Cells?
Current Stem Cell Research & Therapy Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets Recent Advances of MEK Inhibitors and Their Clinical Progress
Current Topics in Medicinal Chemistry